3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
5
Phase 1
5
Phase 2
4
Phase 3
3
Phase NA
1
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
117
Triple Negative Breast Neoplasms
9
Neoplasms
4
Neoplasm Metastasis
4
Lung Neoplasms
4
HER2-positive Breast Cancer
4
Prostatic Neoplasms
3
Motor Activity
3
Melanoma
3
Inflammatory Breast Neoplasms
3
Head and Neck Neoplasms
3
Depression
3
Colorectal Neoplasms
3
Sarcoma
2
Peripheral Nervous System Diseases
2
Ovarian Neoplasms
2
Fatigue
2
Carcinoma, Ductal, Breast
2
Breast Diseases
2
Breast Carcinoma In Situ
2
Anxiety Disorders
2
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Urinary Incontinence
1
To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy in Breast Cancer Patients
1
Smoking
1
Sleepiness
1
Seroma
1
Recurrence
1
Radiodermatitis
1
Interventions
Paclitaxel
1
NVP-BKM120
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Hereditary Sensory and Autonomic Neuropathies
×
Breast
×
Clear all
NCT01572727
2017-03-09
BELLE-4
Novartis
Phase 2/3
Completed
416 enrolled
11 charts